Luini Alberto, Aguilar Marisel, Gatti Giovanna, Fasani Roberta, Botteri Edoardo, Brito Jack Antonio Diaz, Maisonneuve Patrick, Vento Anna Rita, Viale Giuseppe
Division of Breast Surgery, European Institute of Oncology, Milan, Italy.
Breast Cancer Res Treat. 2007 Mar;101(3):349-53. doi: 10.1007/s10549-006-9301-1. Epub 2006 Sep 29.
Metaplastic carcinoma of the breast is a rare form of breast cancer and has an uncertain prognostic significance. The purpose of the present study was to compare the clinical course, and prognosis, between this type of tumor and poorly differentiated ductal carcinoma.
We analyzed 37 cases of metaplastic carcinoma of the breast treated at our institution (European Institute of Oncology in Milan, Italy) between 1997 and 2004, comparing them with 72 cases (control group) of poorly differentiated ductal carcinoma. All 109 patients had negative receptors and were G3 at final histology. The control cases were matched according to year of surgery, pT (pT1 vs. pT2/3/4), and pN (absent vs. present).
Of the 37 patients, eleven died from disease progression, eight developed metastatic disease and two experienced local recurrence. In the control group (72 patients) we observed three deaths due to disease progression, 13 distant metastases, and two local recurrences.
The overall survival in the metaplastic carcinoma group was significantly worse than in the control group. As regards to disease-free survival, there was no statistically significant difference between the two groups.
乳腺化生性癌是一种罕见的乳腺癌类型,其预后意义尚不明确。本研究的目的是比较这种类型的肿瘤与低分化导管癌的临床病程及预后。
我们分析了1997年至2004年间在我们机构(意大利米兰欧洲肿瘤研究所)接受治疗的37例乳腺化生性癌病例,并将其与72例低分化导管癌病例(对照组)进行比较。所有109例患者受体均为阴性,最终组织学分级为G3。对照组根据手术年份、pT(pT1对比pT2/3/4)和pN(无对比有)进行匹配。
37例患者中,11例死于疾病进展,8例发生转移,2例出现局部复发。在对照组(72例患者)中,我们观察到3例死于疾病进展,13例远处转移,2例局部复发。
化生性癌组的总生存率显著低于对照组。关于无病生存率,两组之间无统计学显著差异。